Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.

ABSTRACT:

Introduction

We evaluated for two novel automated biomarker assays how cerebrospinal fluid (CSF) amyloid beta (Aβ)_{1- 42}-ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ_{1- 42} alone.

Methods

We selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer's disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ_{1- 42}, phosphorylated tau (p-tau), and total tau (t-tau) were measured with Elecsys and Lumipulse assays, and Aβ_1-40 with Lumipulse. CSF cut-points were defined using receiver operating characteristic (ROC) for amyloid PET positivity.

Results

For both Elecsys and Lumipulse the p-tau

SUBMITTER: Willemse EAJ 

PROVIDER: S-EPMC8088096 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature